# Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH

> **NCT07690397** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Tecnoquimicas** · enrollment: 140 (estimated)

## Conditions studied

- Primary Open-Angle Glaucoma (POAG)
- Ocular Hypertension

## Interventions

- **COMBINATION_PRODUCT:** Preservative-free dorzolamide-timolol-brimonidine combination
- **COMBINATION_PRODUCT:** Preservative dorzolamide-timolol-brimonidine combination

## Key facts

- **NCT ID:** NCT07690397
- **Lead sponsor:** Tecnoquimicas
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-06-10
- **Primary completion:** 2027-07-10
- **Final completion:** 2027-09-01
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07690397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07690397, "Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07690397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*